HealthCare Royalty Partners, a global healthcare investment firm with $5.5 billion of cumulative capital commitments, announced the closing on $1.83 billion for HealthCare Royalty Partners IV (Fund IV) and affiliated entities.

Since 2003, HCR's senior professionals have invested over $3.0 billion in commercial or near-commercial stage biopharmaceutical products t